Drug Trial Radar · NCT03044184
Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial
Last checked: Nov 20, 2026Latest source record: Oct 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
220
Planned (sponsor's estimate)
Start
Apr 1, 2017
Primary completion
Jun 30, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Kwong Wah HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore the effectiveness of tranexamic acid (also known as trans amine or TXA) in reducing hematoma expansion in patients with hemorrhagic stroke when given in the acute phase. METHODOLOGY This will be a Phase III, parallel-group double-blind randomised placebo control trial. Patients allocated to the control group will receive standard care for hemorrhagic stroke according to the 2015 American Heart Association guidelines. Patients allocated to the intervention group will receive, in addition to standard care, a loading dose of intravenous TXA 1gm within 3 hours of symptom onset followed by a 1gm maintenance dose over 8 hours. Timing and dosing are in accordance to previous established study protocols. Patients in the intervention group will only receive a single treatment course of TXA. Study subjects will be identified by either the on-duty clinicians from the Department of Neurosurgery of this institution or by the study investigators. Should the patient meet study eligibility criteria consent will be obtained either from the patient or from his/her next of kin. 1:1 block randomization will be performed by a remote internet randomization service by accessing a website. Patients allocated to the intervention arm will have 1gm of TXA added to 100ml of normal saline (0.9%) infused over 10 minutes as a loading dose. This is then followed by a maintenance dose of 1gm of TXA in 500ml of intravenous isotonic solution infused at 120mg/hour (60ml/hour) for 8 hours. Patient's allocated to the control arm will have an equal volume of normal saline (0.9%) infused as a placebo. The patient and the outcome assessor will be blinded to study group allocation. The primary endpoint of this study will be to assess the percentage change in brain blood clot volume by computed tomography brain scans on admission, 6 hours later, at 24 hours and at 1 week.
Conditions
- Stroke Hemorrhagic
- Intracerebral Haemorrhage
Interventions
Tranexamic AcidDrug
Transamine is an antifibrinolytic medication given systemically via the intravenous route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intracerebral hematoma volume (by computed tomography brain scan) at 6 hoursTime frame: At 6 hours
- Intracerebral hematoma volume (by computed tomography brain scan) at 24 hoursTime frame: At 24 hours
- Intracerebral hematoma volume (by computed tomography brain scan) at 1 weekTime frame: At 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kwong Wah Hospital
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.